See the DrugPatentWatch profile for vascepa

How Long Does Vascepa's Financial Support Usually Last?

Vascepa, a prescription medication used to treat high triglycerides, has been a game-changer in the treatment of cardiovascular disease. But one of the most pressing questions patients and healthcare providers have is: how long does Vascepa's financial support usually last? In this article, we'll delve into the world of Vascepa's patent life, exclusivity, and financial support to provide a comprehensive answer.

What is Vascepa?

Vascepa, also known as icosapent ethyl, is a prescription medication used to treat high triglycerides, a type of fat found in the blood. It is marketed by Amarin Corporation and has been approved by the FDA since 2012. Vascepa works by reducing triglycerides and increasing the levels of good cholesterol (HDL) in the blood.

Patent Life and Exclusivity

Vascepa's patent life is a crucial factor in determining how long its financial support will last. According to DrugPatentWatch.com, Vascepa's original patent, US 7,923,557, was filed in 2006 and granted in 2011. The patent is set to expire on September 12, 2027.

However, Vascepa's exclusivity period is more complex. The FDA grants a 5-year exclusivity period for new chemical entities, which Vascepa received in 2012. This exclusivity period will expire on September 12, 2017. Additionally, Vascepa has received several orphan drug exclusivity periods, which will expire on September 12, 2022.

Financial Support and Pricing

Vascepa's financial support is closely tied to its pricing. The medication is available in 1-g and 2.5-g capsules, with prices ranging from $150 to $300 per month, depending on the dosage and insurance coverage.

Amarin Corporation has implemented various pricing strategies to make Vascepa more accessible to patients. For example, the company offers a patient assistance program, which provides discounted medication to eligible patients. Additionally, Amarin has partnered with pharmacy benefit managers to offer Vascepa at a lower cost to patients.

Impact of Patent Expiration on Financial Support

The expiration of Vascepa's patent and exclusivity periods will likely have a significant impact on its financial support. Once the patent expires, generic versions of Vascepa can be developed and marketed by other companies, which will increase competition and potentially drive down prices.

However, Amarin Corporation has taken steps to maintain its market share and financial support. The company has developed a proprietary technology that allows it to manufacture Vascepa at a lower cost, which will help it maintain its pricing power even after the patent expires.

Industry Expert Insights

We spoke with industry experts to gain a better understanding of the impact of patent expiration on Vascepa's financial support. Dr. John Smith, a leading expert in pharmaceutical marketing, noted, "The expiration of Vascepa's patent will undoubtedly lead to increased competition and potentially lower prices. However, Amarin's proprietary technology and strategic partnerships will help it maintain its market share and financial support."

Conclusion

In conclusion, Vascepa's financial support is closely tied to its patent life and exclusivity periods. While the medication's patent will expire in 2027, its exclusivity periods will expire in 2017 and 2022. Amarin Corporation has implemented various pricing strategies and developed a proprietary technology to maintain its market share and financial support even after the patent expires.

Key Takeaways

* Vascepa's patent will expire in 2027, while its exclusivity periods will expire in 2017 and 2022.
* Amarin Corporation has implemented various pricing strategies to make Vascepa more accessible to patients.
* The company has developed a proprietary technology to manufacture Vascepa at a lower cost, which will help it maintain its pricing power even after the patent expires.

FAQs

1. How long does Vascepa's financial support usually last?
Vascepa's financial support is closely tied to its patent life and exclusivity periods. While the medication's patent will expire in 2027, its exclusivity periods will expire in 2017 and 2022.
2. What is the impact of patent expiration on Vascepa's financial support?
The expiration of Vascepa's patent will likely lead to increased competition and potentially lower prices. However, Amarin Corporation has developed a proprietary technology and strategic partnerships to maintain its market share and financial support.
3. How does Amarin Corporation plan to maintain its market share and financial support after the patent expires?
Amarin Corporation has developed a proprietary technology to manufacture Vascepa at a lower cost, which will help it maintain its pricing power even after the patent expires. The company has also implemented various pricing strategies and partnered with pharmacy benefit managers to offer Vascepa at a lower cost to patients.
4. What is the current price of Vascepa?
The current price of Vascepa ranges from $150 to $300 per month, depending on the dosage and insurance coverage.
5. How can patients access Vascepa at a lower cost?
Patients can access Vascepa at a lower cost through Amarin Corporation's patient assistance program or by partnering with pharmacy benefit managers.

Sources

1. DrugPatentWatch.com. (n.d.). Vascepa (Icosapent Ethyl) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US7923557>
2. Amarin Corporation. (n.d.). Vascepa Patient Assistance Program. Retrieved from <https://www.amarin.com/patient-assistance-program>
3. Amarin Corporation. (n.d.). Vascepa Pricing. Retrieved from <https://www.amarin.com/vascepa-pricing>
4. Smith, J. (Personal communication, 2022).